Coronavirus: China’s BrightGene Manufactures APIs of Gilead’s Remdesivir

BrightGene Bio-Medical Technology Co., said it has successfully manufactured the active pharmaceutical ingredients (APIs) of remdesivir (GS-5734), the Gilead Science antiviral candidate being tested in China human clinical trials as a treatment for 2019-nCoV novel coronavirus.